Takeda aims for expansion into emerging markets

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) plans to significantly accelerate its expansion in the emerging markets over the next several years, despite the current financial downturn, which is observed in Russia and China, according to Christophe Weber, the firm’s chief executive.

According to Mr Weber, the company does not have any concerns, regarding further development in emerging nations, as their dynamics are cyclical, so the company expects further growth on these markets during the next several years.

It is planned that particular attention of the company will be paid to its further development in the Russian market, the revenue from which in 2014 accounted for only 5% in the Takeda’s overall revenue.